MoonLake Immunotherapeutics
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
The biotech is floating a relatively sizable secondary share issue.
Congressional Trades in $MLTX
No disclosed congressional trades found in $MLTX.
Insider Trades (Form 4)
Reich Kristian
Reich Kristian
BVF PARTNERS L P/IL
Bodenstedt Matthias
Phillips Andrew John
Loy Spike
Moukheibir Catherine
Xavier Ramnik
Key People
Reich Kristian
Chief Scientific Officer
Phillips Andrew John
Director
Bodenstedt Matthias
Chief Financial Officer
Moukheibir Catherine
Director
Loy Spike
Director
BVF PARTNERS L P/IL
Director
Xavier Ramnik
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro